Savaysa
(Edoxaban)ApprovedSmall molecule
Daiichi SankyoEdoxaban is used to prevent blood clots and reduce the risk of stroke in patients with an irregular heartbeat (atrial fibrillation), and to treat blood clots in the legs and lungs.[2] Savaysa is currently approved and in use across 23 indications[4].[1]
Savaysa is one of 480 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
23
Indications
93
Total Trials
16
Active Trials
479
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 22 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Savaysa
Daiichi SankyoApproved
Spikevax
ModernaPreclinical
Stivarga
BayerPreclinical
Aldactone
PfizerPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Rayaldee
OOrganon and Co
Preclinical
Benadryl
PParkedale
Preclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Statins
SanofiPreclinical
Olokizumab
UCBPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atrial Fibrillation32 trials
Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)
Active, not recruiting·—··NCT04010955·1,200 enrolled
Show 29 more trials
EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation
Unknown status·AAzienda Ospedaliero Universitaria Maggiore della Carita·N/A·NCT06285942·168 enrolled
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
Completed·—·Phase 4·NCT03463317·912 enrolled
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
Unknown status·—··NCT04878497·1,000,000 enrolled
Venous Thromboembolism8 trials
Show 5 more trials
Anticoagulant6 trials
Stroke5 trials
Anticoagulation4 trials
32 more indications
Efficacy and Safety3 trials
Coronary Artery Disease2 trials
Safety and Efficacy2 trials
Bariatric Surgery1 trial
Treatment1 trial
Tics1 trial
Intracranial Hemorrhage1 trial
Total Hip Arthroplasty1 trial
Outcome1 trial
Catheter1 trial
Total Knee Arthroplasty1 trial
Cardiac Disease1 trial
Bacteremia1 trial
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT06650501·300 enrolled
Ischemic stroke1 trial
Direct Oral Anticoagulants (DOACs)1 trial
PK/PD1 trial
Heavy Menstrual Bleeding1 trial
Interaction1 trial
Cirrhosis1 trial
DOAC in Patients with Child a or B Liver Cirrhosis
Recruiting·—·Phase 2·NCT05869591·40 enrolled
Clinical Trial1 trial
Unspecified3 trials
The DARE Warfarin CER Study
Unknown status·—··NCT03271450·416,000 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 8, 2015
SAVAYSA
NDA NDA206316
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Savaysa drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Edoxaban. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Coagulation Factor X Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company